Insider · CIK 0001304099
William Hoffman
director
Files at NARI (Inari Medical, Inc.). First filing Oct 18, 2024, latest Jan 8, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 5
$0 bought, $22M sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | Inari Medical, Inc. | $12M 200,000 shares | -46% | - | |
| 40Moderate | Inari Medical, Inc. | $3.3M 60,000 shares | -12% | - | |
| 33Weak | Inari Medical, Inc. | $3.1M 60,000 shares | -11% | - | |
| 28Weak | Inari Medical, Inc. | $2.0M 40,000 shares | -7% | - | |
| 28Weak | Inari Medical, Inc. | $1.8M 40,000 shares | -6% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 19, 2025 | NARI Inari Medical, Inc. | UTender of shares Common Stock | -238,987 | - | - | 0 | Feb 19, 2025 |
| Jan 6, 2025 | NARI Inari Medical, Inc. | SOpen-market sale Common Stock10b5-1 | -141,075 | $60.13 | $8.5M | 297,912 | Jan 8, 2025 |
| Jan 6, 2025 | NARI Inari Medical, Inc. | SOpen-market sale Common Stock10b5-1 | -58,925 | $61.27 | $3.6M | 238,987 | Jan 8, 2025 |
| Jan 1, 2025 | NARI Inari Medical, Inc. | FTax withholding Common Stock | -713 | $51.05 | $36k | 440,520 | Jan 3, 2025 |
| Jan 1, 2025 | NARI Inari Medical, Inc. | FTax withholding Common Stock | -1,533 | $51.05 | $78k | 438,987 | Jan 3, 2025 |
| Dec 16, 2024 | NARI Inari Medical, Inc. | SOpen-market sale Common Stock10b5-1 | -3,176 | $54.33 | $173k | 498,057 | Dec 18, 2024 |
| Dec 16, 2024 | NARI Inari Medical, Inc. | SOpen-market sale Common Stock10b5-1 | -20,917 | $55.23 | $1.2M | 477,140 | Dec 18, 2024 |
| Dec 16, 2024 | NARI Inari Medical, Inc. | SOpen-market sale Common Stock10b5-1 | -13,560 | $56.45 | $765k | 463,580 | Dec 18, 2024 |
| Dec 16, 2024 | NARI Inari Medical, Inc. | SOpen-market sale Common Stock10b5-1 | -2,347 | $56.82 | $133k | 461,233 | Dec 18, 2024 |
| Dec 16, 2024 | NARI Inari Medical, Inc. | SOpen-market sale Common Stock10b5-1 | -2,100 | $54.42 | $114k | 459,133 | Dec 18, 2024 |
| Dec 16, 2024 | NARI Inari Medical, Inc. | SOpen-market sale Common Stock10b5-1 | -10,301 | $55.27 | $569k | 448,832 | Dec 18, 2024 |
| Dec 16, 2024 | NARI Inari Medical, Inc. | SOpen-market sale Common Stock10b5-1 | -7,467 | $56.51 | $422k | 441,365 | Dec 18, 2024 |
| Dec 16, 2024 | NARI Inari Medical, Inc. | SOpen-market sale Common Stock10b5-1 | -132 | $56.89 | $7,509 | 441,233 | Dec 18, 2024 |
| Nov 18, 2024 | NARI Inari Medical, Inc. | SOpen-market sale Common Stock10b5-1 | -3,000 | $50.09 | $150k | 558,233 | Nov 20, 2024 |
| Nov 18, 2024 | NARI Inari Medical, Inc. | SOpen-market sale Common Stock10b5-1 | -33,784 | $51.32 | $1.7M | 524,449 | Nov 20, 2024 |
| Nov 18, 2024 | NARI Inari Medical, Inc. | SOpen-market sale Common Stock10b5-1 | -3,216 | $52.11 | $168k | 521,233 | Nov 20, 2024 |
| Nov 18, 2024 | NARI Inari Medical, Inc. | SOpen-market sale Common Stock10b5-1 | -10,250 | $50.64 | $519k | 510,983 | Nov 20, 2024 |
| Nov 18, 2024 | NARI Inari Medical, Inc. | SOpen-market sale Common Stock10b5-1 | -9,750 | $51.16 | $499k | 501,233 | Nov 20, 2024 |
| Oct 29, 2024 | NARI Inari Medical, Inc. | SOpen-market sale Common Stock10b5-1 | -20,000 | $50.10 | $1.0M | 581,233 | Oct 31, 2024 |
| Oct 29, 2024 | NARI Inari Medical, Inc. | SOpen-market sale Common Stock10b5-1 | -20,000 | $50.00 | $1.0M | 561,233 | Oct 31, 2024 |
| Oct 16, 2024 | NARI Inari Medical, Inc. | SOpen-market sale Common Stock10b5-1 | -27,804 | $44.78 | $1.2M | 613,429 | Oct 18, 2024 |
| Oct 16, 2024 | NARI Inari Medical, Inc. | SOpen-market sale Common Stock10b5-1 | -12,196 | $45.57 | $556k | 601,233 | Oct 18, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.